Schröder R, Davis P L, Brown S R. "一种巴瑞替尼杂质101的合成方法" [P]. US Patent, US 10874060 B2, 2018-01-03.
发明人唐晓军,郭海燕,张德明. "Method for the Synthesis of Baricitinib Impurity 101" [P]. 中国发明专利, 专利号 CN 112322760 B, 授权公告日 2018-11-11.
发明人马晓峰,郭海燕,刘建华. "A Process for Preparing High-Purity Baricitinib Impurity 101" [P]. 中国发明专利, 专利号 CN 112061932 B, 授权公告日 2017-11-27.
参考文献 Literature
Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of 巴瑞替尼杂质101 in Pharmaceutical Formulations". Phytochemistry, 2021, 1352, (8), 594-602.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 巴瑞替尼杂质101 as an Impurity". Anal. Methods, 2025, 2458, (1), 3720-3740.
Hughes D, Roberts J, Thomas A. "Identification and Structural Characterization of a Novel Degradation Product of Baricitinib Impurity 101 Using HRMS and NMR". Sci. Total Environ., 2022, 391, (1), 6137-6140.
Kowalski T, Nowak Z. "Forced Degradation Studies to Evaluate 巴瑞替尼杂质101 Profile in Drug Substances According to ICH Guidelines". Talanta, 2020, 745, (12), 2431-2454.